Refine
Year of publication
Document Type
- Preprint (718)
- Article (703)
- Working Paper (6)
- Conference Proceeding (3)
- Doctoral Thesis (3)
- Report (2)
Has Fulltext
- yes (1435)
Is part of the Bibliography
- no (1435)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- COVID-19 (4)
- Cancer (4)
- Collective Flow (4)
- Depression (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Biomarkers (3)
- Epilepsy (3)
- Genetics (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- Magnetic resonance imaging (3)
- Seizure (3)
- acute myeloid leukemia (3)
- pp collisions (3)
- Accelerators & Beams (2)
- Acute myeloid leukemia (2)
- Algorithms (2)
- Artificial intelligence (2)
- Atomic, Molecular & Optical (2)
- Beauty production (2)
- Biomarker (2)
- Bipolar disorder (2)
- Bone density (2)
- CT (2)
- CV9202 (2)
- Charm physics (2)
- Cohort studies (2)
- Collectivity (2)
- Correlation (2)
- Costs (2)
- Diffraction (2)
- Elastic scattering (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- FGFR (2)
- Frieden (2)
- Friedenskonferenz (2)
- Heavy-ion collisions (2)
- Immunology (2)
- Intensive care units (2)
- Lepton-Nucleon Scattering (experiments) (2)
- MRI (2)
- MSC (2)
- MSC2013 (2)
- Mitochondria (2)
- Multidetector computed tomography (2)
- München (2)
- Neoplasms (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Osteoporosis (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Pre-analytics (2)
- Psychiatric disorders (2)
- QCD (2)
- Quality of life (2)
- Quarkonium (2)
- Relativistic heavy-ion collisions (2)
- SARS-CoV-2 (2)
- Shear viscosity (2)
- Sicherheitskonferenz (2)
- Single electrons (2)
- Spine (2)
- Surgery (2)
- Tomography (2)
- Tomography (x-ray computed) (2)
- apoptosis (2)
- cabozantinib (2)
- childhood acute myeloid leukemia (2)
- computed tomography (2)
- growth inhibition (2)
- immunotherapy (2)
- land use (2)
- liver (2)
- lung cancer (2)
- penile cancer (2)
- portal hypertension (2)
- relapse (2)
- resistant cell lines (2)
- salvage therapy (2)
- security conference (2)
- squamous cell carcinoma (2)
- storage rings (2)
- targeted therapy (2)
- 19F (1)
- 3 mm RAS instruments (1)
- 3 mm instruments (1)
- 3years (1)
- 900 GeV (1)
- ABCB1 (1)
- ABCC1 (1)
- ABCG2 (1)
- ACLF (1)
- ADGRE1 (1)
- AKI (1)
- AKT (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- APRI (1)
- Ablation Techniques (1)
- Accelerators & storage rings (1)
- Acquired drug resistance (1)
- Acquired resistance (1)
- Active middle ear implants (1)
- Acuris (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Adolescents (1)
- Age determination by skeleton (1)
- Age groups (1)
- Aktienmarkt (1)
- Alpha-synuclein (1)
- Alternative oxidase (1)
- Alzheimer (1)
- Amino acid analysis (1)
- Amyloid precursor protein (1)
- Anemia (1)
- Angiography (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Antifungal agents (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Aortic valve replacement (1)
- Applikationen (1)
- Archaeogeophysics (1)
- Artificial Intelligence (1)
- Aspergillosis (1)
- Atomic & molecular beams (1)
- Auditory system (1)
- Autofreies Wohnen (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Autoreduziertes Wohnen (1)
- Awareness campaign (1)
- B cell receptor (1)
- B-slope (1)
- BI1361849 (1)
- Beam loss (1)
- Behavior (1)
- Behavioral disorders (1)
- Bike-Sharing (1)
- Biodiversity (1)
- Biodiversity Data (1)
- Biogeochemistry (1)
- Biological heart valves (1)
- Biomonitoring (1)
- Bioprosthesis (1)
- Biopsy (1)
- Bleeding (1)
- Blood (1)
- Blood sample handling (1)
- Bloodstream infections (1)
- Bone conduction devices (1)
- Bone diseases, Metabolic (1)
- Bone marrow (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brachiopoda (1)
- Brachiozoa (1)
- Breathing (1)
- Bryozoa (1)
- Business strategy in drug development (1)
- C-reactive protein (1)
- CABG (1)
- CAD/ CAM crown (1)
- CAKUT (1)
- CNDAC (1)
- COMT (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CT-guidance (1)
- CTLA-4 (1)
- Calcium (1)
- Cancer Staging (1)
- Cancer check up (1)
- Cancer staging (1)
- Car-Sharing (1)
- Carbon cycle (1)
- Cardiac surgery (1)
- Carsharing (1)
- Cell membranes (1)
- Central Europe (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Checkpoint inhibitor (1)
- Chemicals of emerging concern (1)
- Chemoembolization (1)
- Chemotherapy (1)
- Child abuse (1)
- Childhood abuse (1)
- Children (1)
- Chondral Lesion (1)
- Circular accelerators (1)
- Cirrhosis (1)
- Cleanliness level (1)
- Climate-change ecology (1)
- Clinical genetics (1)
- Clinical trial (1)
- Clinical variation (1)
- Coalescence (1)
- Cochlear implantation (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Combined immune checkpoint blockade (1)
- Combo® DTS (1)
- Community ecology (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Complex II (1)
- Complex posttraumatic stress disorder (1)
- Compositional bias (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computed tomography, X-ray (1)
- Computer-aided drug design (1)
- Cone-beam computed tomography (1)
- Congenital anomalies (1)
- Consensus statement (1)
- Conservation (1)
- Conservation biology (1)
- Contrast agent (1)
- Couch tracking (1)
- Critical point (1)
- Cryoelectron microscopy (1)
- DCK (1)
- DME (1)
- DNA sequence analysis (1)
- DNA taxonomy (1)
- DNA-PAINT (1)
- DSM (1)
- Darmstadt (1)
- Data sharing (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Diagnostic imaging (1)
- Diagnostic markers (1)
- Dialectical behavioural therapy (1)
- Digitization (1)
- Direct oral anticoagulation (1)
- Direct reactions (1)
- Drug screens (1)
- Drug therapy (1)
- Dual-Source CT (1)
- Dual-energy computed tomography (1)
- EGFR (1)
- EMR1 (1)
- ETP-ALL (1)
- East–west divide (1)
- Eating disorders (1)
- Ecological modelling (1)
- Ecological networks (1)
- Ecosystem ecology (1)
- Ectoprocta (1)
- Edema (1)
- Elderly (1)
- Electric stimulation (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Elektromobilität (1)
- Ellenberg indicator values (1)
- Embryos (1)
- Endocannabinoids (1)
- Environmental impact (1)
- European stock markets (1)
- Europäische Aktienmärkte (1)
- Europäische Union (1)
- Everolimus (1)
- Evidence-based guidelines (1)
- Exudates and transudates (1)
- Eye movements (1)
- F4/80 (1)
- FBS (1)
- FFLU (1)
- FIB-4 (1)
- FLT3 (1)
- Facial nerve (1)
- Fahrradverleihsysteme (1)
- Feasibility studies (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flottenkonzepte (1)
- Forest ecology (1)
- Forschung (1)
- Frailty (1)
- Full waveform (1)
- Functional outcomes (1)
- GPS collar (1)
- GWAS (1)
- Gene expression (1)
- General practitioners (1)
- Gimbaled tracking (1)
- Glioblastoma survival (1)
- Global positioning system (1)
- Gram negative bacteria (1)
- Groomed jet radius (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HBT (1)
- HBV (1)
- HCC (1)
- HIV (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronization (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Health information (1)
- Health policy (1)
- Health-seeking behaviour (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion collisions (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Hedgehog pathway (1)
- Helpline (1)
- Hematologic malignancies (1)
- Hematology (1)
- Hematopoietic stem cell transplantation (1)
- Hepatitis C virus (1)
- Herbaria (1)
- Herniated disk (1)
- Hif-1 alpha (1)
- High-dose chemotherapy (1)
- Higher moments (1)
- Hodgkin lymphoma (1)
- Hsp70 (1)
- Hypertension (1)
- Hypochondriasis (1)
- Hypofractionated radiotherapy (1)
- ICL (1)
- ICL V4c (1)
- IHC (1)
- ILUVIEN (1)
- INR (1)
- Image processing (1)
- Image processing (computer-assisted) (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- In-TIPS thrombosis (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Inflammation (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- International normalized ratio (1)
- Interpretation (1)
- Intervertebral disc displacement (1)
- Intrinsic resistance (1)
- Invariant Mass Distribution (1)
- Invasive candidiasis (1)
- Inversion (1)
- Ionisation energy loss (1)
- Ipilimumab (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- K3EDTA plasma sampling (1)
- KDIGO (1)
- Kidney (1)
- Knockout (1)
- Kryptrochozoa (1)
- LVSPE (1)
- Ladeinfrastruktur (1)
- Lehre (1)
- Lenalidomide (1)
- Leukemia (1)
- Leukemias (1)
- Library screening (1)
- Lincoln-Siedlung (1)
- Lipidol (1)
- Lipidomics (1)
- Liver (1)
- Liver diseases (1)
- Liver transplantation (1)
- Local control (1)
- Lophophorata (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Low-molecular-weight heparin (1)
- Luciferase (1)
- MALAT1 (1)
- MEDIC (1)
- MLC tracking (1)
- MTOR inhibitor (1)
- MYC (1)
- Mass spectrometry (1)
- Mastoiditis (1)
- Material budget (1)
- Medical Oncology (1)
- Melanoma (1)
- Mental health and psychiatry (1)
- Meriç River (1)
- Metabolomics (1)
- Metastasis (1)
- Micropollutants (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitfahrangebote (1)
- Mitochondrial disease (1)
- Mitoxantrone (1)
- Mixed hearing loss (1)
- Mixture risk assessment (1)
- Mobil-Stationen (1)
- Mobilität (1)
- Mobilitätskonzept (1)
- Mobilitätsstationen (1)
- Mobilitätsverhalten (1)
- Model of evolution (1)
- Molecular diagnostic testing (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multidetector Computed Tomography (1)
- Multifaktorenmodelle (1)
- Multimodalität (1)
- Multiple factor models (1)
- Multiple myeloma (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- Mutation databases (1)
- Mycoses (1)
- Myocarditis (1)
- Myopia (1)
- NAFLD (1)
- NK cells (1)
- NMR spectroscopy (1)
- NOTCH (1)
- NOTCH1 (1)
- NSF (1)
- NVBP (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Neural network (1)
- Neuronal morphology (1)
- Neuroscience (1)
- Neutropenia (1)
- Nivolumab (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Obsessive-compulsive disorder (1)
- Oldest-old (1)
- Organ motion (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- Oxygen (1)
- PD-1 (1)
- PD-L1 (1)
- PLX4032 (1)
- PLX4720 (1)
- PRoMPT (1)
- PSA screening (1)
- PSA-Screening (1)
- PTEN (1)
- PYTHIA (1)
- Parken (1)
- Parkinson’s disease (1)
- Particle and Resonance Production (1)
- Patellofemoral Joint (1)
- Patterns of care (1)
- Pb–Pb (1)
- Pedelecs (1)
- Personenmobilität (1)
- Phakic (1)
- Phantoms (imaging) (1)
- Phoronida (1)
- Phosphate (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- Phylloscopidae (1)
- Phylloscopus (1)
- Phylogeography (1)
- PillCamColon2 (1)
- Plasma (1)
- Point-of-care testing (1)
- Polarization (1)
- Polyps (1)
- Polysomnography (1)
- Polyzoa (1)
- Positive fluid balance (1)
- Positron emission tomography (1)
- Post-traumatic stress disorder (1)
- Postoperative atrial fibrillation (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Prävention (1)
- Psoriasis vulgaris (1)
- Psychological and psychosocial issues (1)
- Pulmonary embolism (1)
- QGP (1)
- QSARs (1)
- Quantitative Imaging (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RHIC (1)
- RNA (1)
- RNA, long noncoding (1)
- RNActive (1)
- RSL curve (1)
- Radiation detectors (1)
- Radical prostatectomy (1)
- Radiology (1)
- Radiomics (1)
- Radiotherapy (1)
- Randomised controlled trial (1)
- Rapidity Range (1)
- Rare diseases (1)
- Region Rhein-Main (1)
- Registries (1)
- Rehabilitation (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Renal cell carcinoma (1)
- Research (1)
- Research Infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Respiration (1)
- Respiratory chain (1)
- Retro-IDEAL (1)
- Retrospective studies (1)
- Retrospective study (1)
- Rhabdomyoma (1)
- Ribosome (1)
- Risk drivers (1)
- River pollution (1)
- Robotic tracking (1)
- SAMHD1 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SLC20A1 (1)
- SMAD (1)
- SPSS (1)
- STIR (1)
- Salivary gland carcinoma (1)
- Sampling protocol (1)
- Sapacitabine (1)
- Second-line treatment (1)
- Seicercus (1)
- Semantics (1)
- Senescence (1)
- Sequence (1)
- Serum (1)
- Shell model (1)
- Single muons (1)
- Sleep (1)
- Sleep deprivation (1)
- Small molecules (1)
- Social anxiety disorder (1)
- Sociodemographic characteristics (1)
- SoftDrop (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Spinal fractures (1)
- Spine density (1)
- Splitting function (1)
- Stenotrophomonas maltophilia (1)
- Steroid (1)
- Subependymal giant cell astrocytoma (1)
- Surface waters (1)
- Surveys (1)
- Survival analysis (1)
- Survival data (1)
- Systematic Uncertainty (1)
- Systemic treatment (1)
- T-ALL (1)
- TGFβ (1)
- TGR(mREN2)27 (1)
- TIPS (1)
- TP53 mutation status (1)
- TR (1)
- TSC (1)
- Target screening (1)
- Targeted therapy (1)
- Taxonomy (1)
- Teaching (1)
- Technical data (1)
- Telemedicine (1)
- Territorial songs (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Tracking (1)
- Traditional Chinese Medicine (TCM) (1)
- Transcriptome analysis (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment (1)
- Trigger (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- USP28 (1)
- Umweltbilanz (1)
- University hospitals (1)
- Universitätskliniken (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Ursus arctos (1)
- Uveal melanoma (1)
- VEGFR (1)
- Vaccination (1)
- Valve surgery (1)
- Vasculitis (1)
- Vector Boson Production (1)
- Vemurafenib (1)
- Vesicles (1)
- Vincristine (1)
- Virtual noncalcium reconstructions (1)
- Vorsorgeuntersuchung (1)
- Weiterbildung (1)
- Western diet (1)
- Wohnumzug (1)
- X-ray computed (1)
- X-rays (1)
- Xenon-based gas mixture (1)
- abdominal imaging (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- activity sensors (1)
- acute decompensation (1)
- acute lymphoblastic leukemia (1)
- acute-on-chronic liver failure (1)
- adjuvant chemotherapy (1)
- aegean (1)
- age (1)
- amino acids (1)
- amphiregulin (1)
- amygdalin (1)
- anaplastic large cell lymphoma (1)
- angiography (1)
- anterior chamber depth changes (1)
- anti-EGFR therapy (1)
- antiepileptic drugs (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- aortic stenosis (1)
- archeological sea-level limiting points (1)
- artesunate (ART) (1)
- artifacts (1)
- artificial intelligence (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- autophagy (1)
- bacterial leakage (1)
- beads (1)
- bioactivity testing (1)
- biogeographic legaciese (1)
- bioindication (1)
- biomarker (1)
- bladder cancer (BCa) (1)
- bladder exstrophy-epispadias complex (1)
- breast cancer (1)
- brown bear (1)
- c-MET (1)
- cabazitaxel (1)
- carbapenem resistance (1)
- cardiac arrest (1)
- cardiac remodeling (1)
- case study (1)
- castration resistance (1)
- cataract surgery (1)
- cell lines (1)
- cell therapy (1)
- cell-free protein synthesis (1)
- characteristic species (1)
- chemorefractory metastatic colorectal cancer (1)
- children and adolescents (1)
- chronic total occlusion (1)
- cilia (1)
- cirrhosis (1)
- cisplatin resistance (1)
- cloacal malformation (1)
- coastal geomorphology (1)
- colorectal cancer (1)
- complementary/alternative medicine (CAM) (1)
- computer tomography (1)
- computer-assisted (1)
- conical coupling (1)
- conometric connection (1)
- corneas (1)
- cryptic species (1)
- cytarabine dose (1)
- dE/dx (1)
- data quality (1)
- depression (1)
- deswelling (1)
- detector (1)
- diagnostic imaging (1)
- differentiating species (1)
- disease prevalence (1)
- docetaxel (1)
- docetaxel (DX) resistance (1)
- drug resistance (1)
- dual-energy (1)
- easyPACId (1)
- ectosomes (1)
- effective lens position (1)
- elderly (1)
- electrical resistivity tomography (1)
- electroencephalography (EEG) (1)
- eltrombopag (1)
- energy-dispersive x-ray spectroscopy (1)
- epigenomics (1)
- epiregulin (1)
- ethical trade-off (1)
- eutrophication (1)
- excitation (1)
- exosomes (1)
- experimental results (1)
- explainable AI (1)
- extinction (1)
- extracellular vesicles (1)
- fear conditioning (1)
- fibrotest (1)
- fluorine (1)
- foraminifera (1)
- foraminifers (1)
- forest classification (1)
- forest functional similarity (1)
- fragment-based screening (1)
- functional genetics (1)
- gadobutrol (1)
- gene family (1)
- genetic generalized epilepsy (1)
- genome evolution (1)
- geophysical prospections (1)
- germ cell tumors (1)
- glioblastoma (1)
- glioblastoma survival (1)
- global change (1)
- graft rejection (1)
- graft-versus host (1)
- grasshopper communities (1)
- guidelines (1)
- habitat destruction (1)
- head-and-neck cancer (1)
- health information exchange (1)
- healthcare (1)
- heart failure (1)
- heavy ion experiments (1)
- hepatic encephalopathy (1)
- hepatocellular carcinoma (1)
- high-pitch (1)
- highly-charged ions (1)
- histology (1)
- hospital exemption (1)
- human cytomegalovirus (1)
- human knockout model (1)
- hypertension, pulmonary (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immunity (1)
- immunohistochemistry (1)
- in vivo dosimetry (1)
- infection control (1)
- integrative taxonomy (1)
- interoperability (1)
- interventional radiology (1)
- intraarterial therapy (1)
- intrinsically disordered region (1)
- invasive species (1)
- iron chelation (1)
- ischemic type biliary lesions (1)
- keratoplasty (1)
- kidney formation (1)
- kinase inhibitor (1)
- knockout mouse (1)
- lamotrigine (1)
- learning (1)
- levetiracetam (1)
- liver fibrosis (1)
- liver metastases (1)
- liver metastasis (1)
- liver transplantation (1)
- livermetastases of colorectal cancer (1)
- local radiotherapy (1)
- locoregional chemotherapy (1)
- long non-coding RNA (1)
- low-dose imaging (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- mTOR (1)
- mTOR inhibitor (1)
- macrophage (1)
- magnetic gradiometry (1)
- marginal fit (1)
- marker (1)
- medial prefrontal cortex (mPFC) (1)
- memory consolidation and extinction (1)
- mesenchymal stromal cell (1)
- metastasis (1)
- metastatic prostate cancer (1)
- microdosing (1)
- microkeratome (1)
- microlaparoscopy (1)
- micropalaeontology (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- minimally invasive surgery (1)
- molecular characteristics (1)
- mortality (1)
- motility (1)
- multicenter study (1)
- multidetector computed tomography (1)
- multivariate mixed model (1)
- natural products (1)
- necroptosis (1)
- neovascularization, physiologic (1)
- neutralizing antibodies (1)
- nitrogen deposition (1)
- nocardia (1)
- nocardiosis (1)
- non-invasive fibrosis assessment (1)
- non-small cell lung cancer (1)
- nonstructural proteins (1)
- optical coherence tomography (1)
- orthology (1)
- orthopic liver transplantation (1)
- ovary (1)
- p+p collisions (1)
- pIOL (1)
- pediatric (1)
- pediatric patients (1)
- pediatric robotic surgery (1)
- personality (1)
- pharmacoresistance (1)
- phylogenetic community distance (1)
- phylogenetic signal (1)
- point shear wave elastography (1)
- portal vein (1)
- portosystemic shunt (1)
- predictive biomarkers (1)
- prognostic biomarker (1)
- prostate cancer (1)
- prostate cancer (PCa) (1)
- proteins (1)
- proteobacteria (1)
- proteomics (1)
- pseudoexfoliative syndrome (1)
- pulmonary embolism (1)
- pulmonary nocardiosis (1)
- qualitative research (1)
- quality control (1)
- quantum electrodynamics test (1)
- quark gluon plasma (1)
- radiation dosage (1)
- radiation dosimetry (1)
- radiation protection (1)
- radiomics (1)
- rare diseases (1)
- rats (1)
- re-exposure (1)
- rechallenge (1)
- recurrence pattern (1)
- refractory aGvHD (1)
- reintroduction (1)
- relativistic collisions (1)
- renal impairment (1)
- repeatability (1)
- reproducibility (1)
- resistance (1)
- retrospective trial (1)
- rigor (1)
- robotically assisted surgery (1)
- robotics (1)
- schizophrenia (1)
- sea-level indicator (1)
- semi-dry grassland (1)
- sequential ALK-inhibitor therapy (1)
- sex (1)
- shikonin (SHI) (1)
- simplified production (1)
- single subject classification (1)
- smart home (1)
- smart living (1)
- soil nutrients (1)
- song evolution (1)
- spectra (1)
- sphingolipids (1)
- spike protein (1)
- spontaneous portosystemic shunt (1)
- stage II/III colorectal cancer (1)
- standardization (1)
- steroid-resistant aGvHD (1)
- strong Coulomb field (1)
- structural habitat types (1)
- structural proteins (1)
- survival (1)
- temporal classification (1)
- testis (1)
- therapeutic anticoagulation (1)
- thrombopietin receptor agonist (1)
- thrombosis (1)
- tivantinib (1)
- transcranial magnetic stimulation (TMS) (1)
- transient elastography (1)
- transmission (1)
- transplantation (1)
- treatment resistance (1)
- tropical forests (1)
- trust (1)
- trustworthy AI (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (TKI) (1)
- urinary tract development (1)
- uveal melanoma (1)
- valproic acid (1)
- variants of concern (1)
- vegetation-plot data (1)
- web of things (1)
- whole-genome sequencing (1)
- x-ray techniques (1)
- zebrafish development (1)
- Öffentlichkeit (1)
- ΔNp63 (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1124)
- Frankfurt Institute for Advanced Studies (FIAS) (995)
- Informatik (925)
- Medizin (166)
- Geowissenschaften (39)
- Institut für Ökologie, Evolution und Diversität (14)
- Biowissenschaften (13)
- Biodiversität und Klima Forschungszentrum (BiK-F) (10)
- Senckenbergische Naturforschende Gesellschaft (8)
- ELEMENTS (7)
Results are presented on event-by-event electric charge fluctuations in central Pb+Pb collisions at 20, 30, 40, 80 and 158 AGeV. The observed fluctuations are close to those expected for a gas of pions correlated by global charge conservation only. These fluctuations are considerably larger than those calculated for an ideal gas of deconfined quarks and gluons. The present measurements do not necessarily exclude reduced fluctuations from a quark-gluon plasma because these might be masked by contributions from resonance decays.
System-size dependence of strangeness production in nucleus-nucleus collisions at √sNN = 17.3 GeV
(2005)
Emission of pi, K, phi and Lambda was measured in near-central C+C and Si+Si collisions at 158 AGeV beam energy. Together with earlier data for p+p, S+S and Pb+Pb, the system-size dependence of relative strangeness production in nucleus-nucleus collisions is obtained. Its fast rise and the saturation observed at about 60 participating nucleons can be understood as onset of the formation of coherent partonic subsystems of increasing size. PACS numbers: 25.75.-q
Production of Lambda and Antilambda hyperons was measured in central Pb-Pb collisions at 40, 80, and 158 A GeV beam energy on a fixed target. Transverse mass spectra and rapidity distributions are given for all three energies. The Lambda/pi ratio at mid-rapidity and in full phase space shows a pronounced maximum between the highest AGS and 40 A GeV SPS energies, whereas the anti-Lambda}/pi ratio exhibits a monotonic increase. PACS numbers: 25.75.-q
Results are presented on Omega production in central Pb+Pb collisions at 40 and 158 AGeV beam energy. Given are transverse-mass spectra, rapidity distributions, and total yields for the sum Omega+Antiomega at 40 AGeV and for Omega and Antiomega separately at 158 AGeV. The yields are strongly under-predicted by the string-hadronic UrQMD model and are in better agreement with predictions from a hadron gas models. PACS numbers: 25.75.Dw
Particle production in central Pb+Pb collisions was studied with the NA49 large acceptance spectrometer at the CERN SPS at beam energies of 20, 30, 40, 80, and 158 GeV per nucleon. A change of the energy dependence is observed around 30A GeV for the yields of pions and strange particles as well as for the shapes of the transverse mass spectra. At present only a reaction scenario with onset of deconfinement is able to reproduce the measurements.
The hadronic final state of central Pb+Pb collisions at 20, 30, 40, 80, and 158 AGeV has been measured by the CERN NA49 collaboration. The mean transverse mass of pions and kaons at midrapidity stays nearly constant in this energy range, whereas at lower energies, at the AGS, a steep increase with beam energy was measured. Compared to p+p collisions as well as to model calculations, anomalies in the energy dependence of pion and kaon production at lower SPS energies are observed. These findings can be explained, assuming that the energy density reached in central A+A collisions at lower SPS energies is sufficient to transform the hot and dense nuclear matter into a deconfined phase.
The hadronic final state of central Pb+Pb collisions at 20, 30, 40, 80, and 158 AGeV has been measured by the CERN NA49 collaboration. The mean transverse mass of pions and kaons at midrapidity stays nearly constant in this energy range, whereas at lower energies, at the AGS, a steep increase with beam energy was measured. Compared to p+p collisions as well as to model calculations, anomalies in the energy dependence of pion and kaon production at lower SPS energies are observed. These findings can be explained, assuming that the energy density reached in central A+A collisions at lower SPS energies is sufficient to force the hot and dense nuclear matter into a deconfined phase.
Introduction: Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) occurs approximately 1 in 3.500 live births representing the most common malformation of the upper digestive tract. Only half a century ago, EA/TEF was fatal among affected newborns suggesting that the steady birth prevalence might in parts be due to mutational de novo events in genes involved in foregut development.
Methods: To identify mutational de novo events in EA/TEF patients, we surveyed the exome of 30 case-parent trios. Identified and confirmed de novo variants were prioritized using in silico prediction tools. To investigate the embryonic role of genes harboring prioritized de novo variants we performed targeted analysis of mouse transcriptome data of esophageal tissue obtained at the embryonic day (E) E8.5, E12.5, and postnatal.
Results: In total we prioritized 14 novel de novo variants in 14 different genes (APOL2, EEF1D, CHD7, FANCB, GGT6, KIAA0556, NFX1, NPR2, PIGC, SLC5A2, TANC2, TRPS1, UBA3, and ZFHX3) and eight rare de novo variants in eight additional genes (CELSR1, CLP1, GPR133, HPS3, MTA3, PLEC, STAB1, and PPIP5K2). Through personal communication during the project, we identified an additional EA/TEF case-parent trio with a rare de novo variant in ZFHX3. In silico prediction analysis of the identified variants and comparative analysis of mouse transcriptome data of esophageal tissue obtained at E8.5, E12.5, and postnatal prioritized CHD7, TRPS1, and ZFHX3 as EA/TEF candidate genes. Re-sequencing of ZFHX3 in additional 192 EA/TEF patients did not identify further putative EA/TEF-associated variants.
Conclusion: Our study suggests that rare mutational de novo events in genes involved in foregut development contribute to the development of EA/TEF.
Tumor cells frequently overexpress heat shock protein 70 (Hsp70) and present it on their cell surface, where it can be recognized by pre‐activated NK cells. In our retrospective study the expression of Hsp70 was determined in relation to tumor‐infiltrating CD56+ NK cells in formalin‐fixed paraffin embedded (FFPE) tumor specimens of patients with SCCHN (N = 145) as potential indicators for survival and disease recurrence. All patients received radical surgery and postoperative cisplatin‐based radiochemotherapy (RCT). In general, Hsp70 expression was stronger, but with variable intensities, in tumor compared to normal tissues. Patients with high Hsp70 expressing tumors (scores 3–4) showed significantly decreased overall survival (OS; p = 0.008), local progression‐free survival (LPFS; p = 0.034) and distant metastases‐free survival (DMFS; p = 0.044), compared to those with low Hsp70 expression (scores 0–2), which remained significant after adjustment for relevant prognostic variables. The adverse prognostic value of a high Hsp70 expression for OS was also observed in patient cohorts with p16‐ (p = 0.001), p53‐ (p = 0.0003) and HPV16 DNA‐negative (p = 0.001) tumors. The absence or low numbers of tumor‐infiltrating CD56+ NK cells also correlated with significantly decreased OS (p = 0.0001), LPFS (p = 0.0009) and DMFS (p = 0.0001). A high Hsp70 expression and low numbers of tumor‐infiltrating NK cells have the highest negative predictive value (p = 0.00004). In summary, a strong Hsp70 expression and low numbers of tumor‐infiltrating NK cells correlate with unfavorable outcome following surgery and RCT in patients with SCCHN, and thus serve as negative prognostic markers.
Increasing atmospheric CO2 stimulates photosynthesis which can increase net primary production (NPP), but at longer timescales may not necessarily increase plant biomass. Here we analyse the four decade-long CO2-enrichment experiments in woody ecosystems that measured total NPP and biomass. CO2 enrichment increased biomass increment by 1.05 ± 0.26 kg C m−2 over a full decade, a 29.1 ± 11.7% stimulation of biomass gain in these early-secondary-succession temperate ecosystems. This response is predictable by combining the CO2 response of NPP (0.16 ± 0.03 kg C m−2 y−1) and the CO2-independent, linear slope between biomass increment and cumulative NPP (0.55 ± 0.17). An ensemble of terrestrial ecosystem models fail to predict both terms correctly. Allocation to wood was a driver of across-site, and across-model, response variability and together with CO2-independence of biomass retention highlights the value of understanding drivers of wood allocation under ambient conditions to correctly interpret and predict CO2 responses.
Background and Aims: The prevalence of hepatitis C virus (HCV) antibodies in Germany has been estimated to be in the range of 0.4–0.63%. Screening for HCV is recommended in patients with elevated ALT levels or significant risk factors for HCV transmission only. However, 15–30% of patients report no risk factors and ALT levels can be normal in up to 20–30% of patients with chronic HCV infection. The aim of this study was to assess the HCV seroprevalence in patients visiting two tertiary care emergency departments in Berlin and Frankfurt, respectively.
Methods: Between May 2008 and March 2010, a total of 28,809 consecutive patients were screened for the presence of anti-HCV antibodies. Anti-HCV positive sera were subsequently tested for HCV-RNA.
Results: The overall HCV seroprevalence was 2.6% (95% CI: 2.4–2.8; 2.4% in Berlin and 3.5% in Frankfurt). HCV-RNA was detectable in 68% of anti-HCV positive cases. Thus, the prevalence of chronic HCV infection in the overall study population was 1.6% (95% CI 1.5–1.8). The most commonly reported risk factor was former/current injection drug use (IDU; 31.2%) and those with IDU as the main risk factor were significantly younger than patients without IDU (p<0.001) and the male-to-female ratio was 72% (121 vs. 46 patients; p<0.001). Finally, 18.8% of contacted HCV-RNA positive patients had not been diagnosed previously.
Conclusions: The HCV seroprevalence was more than four times higher compared to current estimates and almost one fifth of contacted HCV-RNA positive patients had not been diagnosed previously.
Background: Intestinal perforation or leakage increases morbidity and mortality of surgical and endoscopic interventions. We identified criteria for use of full-covered, extractable self-expanding metal stents (cSEMS) vs. "Over the scope"-clips (OTSC) for leak closure.
Methods: Patients who underwent endoscopic treatment for postoperative leakage, endoscopic perforation, or spontaneous rupture of the upper gastrointestinal tract between 2006 and 2013 were identified at four tertiary endoscopic centers. Technical success, outcome (e.g. duration of hospitalization, in-hospital mortality), and complications were assessed and analyzed with respect to etiology, size and location of leakage.
Results: Of 106 patients (male: 75 (71%), female: 31 (29%); age (mean ± SD): 62.5 ± 1.3 years, 72 (69%) were treated by cSEMS and 34 (31%) by OTSC. For cSEMS vs. OTSC, mean treatment duration was 41.1 vs. 25 days, p<0.001, leakage size 10 (1-50) vs. 5 (1-30) mm (median (range)), and complications were observed in 68% vs. 8.8%, p<0.001, respectively. Clinical success for primary interventional treatment was observed in 29/72 (40%) vs. 24/34 (70%, p = 0.006), and clinical success at the end of follow-up was 46/72 (64%) vs. 29/34 (85%) for patients treated by cSEMS vs. OTSC; p = 0.04.
Conclusion: OTSC is preferred in small-sized lesions and in perforation caused by endoscopic interventions, cSEMS in patients with concomitant local infection or abscess. cSEMS is associated with a higher frequency of complications. Therefore, OTSC might be preferred if technically feasible. Indication criteria for cSEMS vs. OTSC vary and might impede design of randomized studies.
Background: Posttraumatic stress disorder (PTSD) after childhood abuse (CA) is often related to severe co-occurring psychopathology, such as symptoms of borderline personality disorder (BPD). The ICD-11 has included Complex PTSD as a new diagnosis, which is defined by PTSD symptoms plus disturbances in emotion regulation, self-concept, and interpersonal relationships. Unfortunately, the empirical database on psychosocial treatments for survivors of CA is quite limited. Furthermore, the few existing studies often have either excluded subjects with self-harm behaviour and suicidal ideation — which is common behaviour in subjects suffering from Complex PTSD. Thus, researchers are still trying to identify efficacious treatment programmes for this group of patients.
We have designed DBT-PTSD to meet the specific needs of patients with Complex PTSD. The treatment programme is based on the rules and principles of dialectical behavioural therapy (DBT), and adds interventions derived from cognitive behavioural therapy, acceptance and commitment therapy and compassion-focused therapy. DBT-PTSD can be provided as a comprehensive residential programme or as an outpatient programme. The effects of the residential programme were evaluated in a randomised controlled trial. Data revealed significant reduction of posttraumatic symptoms, with large between-group effect sizes when compared to a treatment-as-usual wait list condition (Cohen’s d = 1.5).
The first aim of this project on hand is to evaluate the efficacy of the outpatient DBT-PTSD programme. The second aim is to identify the major therapeutic variables mediating treatment efficacy. The third aim is to study neural mechanisms and treatment sensitivity of two frequent sequelae of PTSD after CA: intrusions and dissociation.
Methods: To address these questions, we include female patients who experienced CA and who fulfil DSM-5 criteria for PTSD plus borderline features, including criteria for severe emotion dysregulation. The study is funded by the German Federal Ministry of Education and Research, and started in 2014. Participants are randomised to outpatient psychotherapy with either DBT-PTSD or Cognitive Processing Therapy. Formal power analysis revealed a minimum of 180 patients to be recruited. The primary outcome is the change on the Clinician-Administered PTSD Scale for DSM-5.
Discussion: The expected results will be a major step forward in establishing empirically supported psychological treatments for survivors of CA suffering from Complex PTSD.
Trial registration: German Clinical Trials Register: registration number DRKS00005578, date of registration 19 December 2013.
Early experiences of childhood sexual or physical abuse are often associated with functional impairments, reduced well-being and interpersonal problems in adulthood. Prior studies have addressed whether the traumatic experience itself or adult psychopathology is linked to these limitations. To approach this question, individuals with posttraumatic stress disorder (PTSD) and healthy individuals with and without a history of child abuse were investigated. We used global positioning system (GPS) tracking to study temporal and spatial limitations in the participants’ real-life activity space over the course of one week. The sample consisted of 228 female participants: 150 women with PTSD and emotional instability with a history of child abuse, 35 mentally healthy women with a history of child abuse (healthy trauma controls, HTC) and 43 mentally healthy women without any traumatic experiences in their past (healthy controls, HC). Both traumatized groups—i.e. the PTSD and the HTC group—had smaller movement radii than the HC group on the weekends, but neither spent significantly less time away from home than HC. Some differences between PTSD and HC in movement radius seem to be related to correlates of PTSD psychopathology, like depression and physical health. Yet group differences between HTC and HC in movement radius remained even when contextual and individual health variables were included in the model, indicating specific effects of traumatic experiences on activity space. Experiences of child abuse could limit activity space later in life, regardless of whether PTSD develops.
Folgende Publikationen werden rezensiert: Garve & al.: Verbreitungsatlas Niedersachsen, Hölzel & al.: Stromtalwiesen, Lübcke & Frede: Naturschutzgebiete in Hessen Band 4, Notizbuch 68 der Kasseler Schule, Riecken & al.: Rote Liste Biotoptypen, Schulz & Dengler: Verbreitungsatlas Moose Schleswig-Holstein, Szabo: Wandern – Erkennen – Heilen
Whereas the lack of biomarkers in penile cancer (PeCa) impedes the development of efficacious treatment protocols, preliminary evidence suggests that c-MET and associated signaling elements may be dysregulated in this disorder. In the following study, we investigated whether c-MET and associated key molecular elements may have prognostic and therapeutic utility in PeCa. Formalin-fixed, paraffin-embedded tumor tissue from therapy-naïve patients with invasive PeCa was used for tissue microarray (TMA) analysis. Immunohistochemical staining was performed to determine the expression of the proteins c-MET, PPARg, β-catenin, snail, survivin, and n-MYC. In total, 94 PeCa patients with available tumor tissue were included. The median age was 64.9 years. High-grade tumors were present in 23.4%, and high-risk HPV was detected in 25.5%. The median follow-up was 32.5 months. High expression of snail was associated with HPV-positive tumors. Expression of β-catenin was inversely associated with grading. In both univariate COX regression analysis and the log-rank test, an increased expression of PPARg and c-MET was predictive of inferior disease-specific survival (DSS). Moreover, in multivariate analysis, a higher expression of c-MET was independently associated with worse DSS. Blocking c-MET with cabozantinib and tivantinib induced a significant decrease in viability in the primary PeCa cell line UKF-PeC3 isolated from the tumor tissue as well as in cisplatin- and osimertinib-resistant sublines. Strikingly, a higher sensitivity to tivantinib could be detected in the latter, pointing to the promising option of utilizing this agent in the second-line treatment setting.
Purpose: To evaluate intermediate and long-term visual outcomes and safety of a phakic intraocular posterior chamber lens with a central hole (ICL V4c) for myopic eyes.
Methods: Retrospective, consecutive case study of patients that uneventfully received a ICL V4c for myopia correction, with a 5-year postoperative follow-up. Department of Ophthalmology, Goethe University Frankfurt, Germany.
Results: From 241 eyes that underwent ICL implantation, we included 45 eyes with a mean age at surgery of 33 years ± 6 (18–48 years), with a 5 years follow-up. CDVA improved from 0.05logMAR ± 0.15 CDVA preoperatively to − 0.00 ± 0,07 at 5 years and did not change significantly from 3 to 5 years’ time (p = 0.266). The mean spherical equivalent (SE) improved from -10.13D ± 3.39 to − 0.45D ± 0.69. The change in endothelial cell count showed a mean decrease of 1.9% per year throughout the follow-up. Safety and efficacy index were 1.16 and 0.78, respectively. Cataract formation was seen in 2 of 241 eyes (0.8%), but in none of the 45 eyes that finished the 5-year follow-up.
Conclusions: Our data show a good intermediate and long-term stability, efficiency, and safety of ICL V4c phakic lenses in myopic eyes comparable to other known literature.
In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis. Besides the different clinical presentations of these lymphoma entities, there are variants of NLPHL with considerable histopathologic overlap compared to THRLBCL. Especially THRLBCL-like NLPHL, a diffuse form of NLPHL, often presents a histopathologic pattern similar to THRLBCL, suggesting a close relationship between both lymphoma entities. To corroborate this hypothesis, we performed gene expression profiling of microdissected tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. In unsupervised analyses, the lymphomas did not cluster according to their entity. Moreover, even in supervised analyses, very few consistently differentially expressed transcripts were found, and for these genes the extent of differential expression was only moderate. Hence, there are no clear and consistent differences in the gene expression of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. Based on the gene expression studies, we identified BAT3/BAG6, HIGD1A, and FAT10/UBD as immunohistochemical markers expressed in the tumor cells of all three lymphomas. Characterization of the tumor microenvironment for infiltrating T cells and histiocytes revealed significant differences in the cellular composition between typical NLPHL and THRLBCL cases. However, THRLBCL-like NLPHL presented a histopathologic pattern more related to THRLBCL than NLPHL. In conclusion, NLPHL and THRLBCL may represent a spectrum of the same disease. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma microenvironment, possibly related to the immune status of the patient at the timepoint of diagnosis.
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
Background: Glioblastoma (GBM) patients are at particularly high risk for thrombotic complications. In the event of a postoperative pulmonary embolism, therapeutic anticoagulation (tAC) is indispensable. The impact of therapeutic anticoagulation on recurrence pattern in GBM is currently unknown. Methods: We conducted a matched-pair cohort analysis of 57 GBM patients with or without tAC that were matched for age, sex, gross total resection and MGMT methylation status in a ratio of 1:2. Patients’ characteristics and clinical course were evaluated using medical charts. MRI characteristics were evaluated by two independent authors blinded to the AC status. Results: The morphologic MRI appearance in first GBM recurrence showed a significantly higher presence of multifocal, midline crossing and sharp demarcated GBM recurrence patterns in patients with therapeutic tAC compared to the matched control group. Although statistically non-significant, the therapeutic tAC cohort showed increased survival. Conclusion: Therapeutic anticoagulation induced significant morphologic changes in GBM recurrences. The underlying pathophysiology is discussed in this article but remains to be further elucidated.
Background: Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label.
Methods: A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT-scan confirmed, PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data.
Results: Out of 584 GBM patients, 8% suffered from postoperative PE. Out of theses, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6- and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS.
Conclusion: In our analysis DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
This prospective study sought to evaluate potential savings of radiation dose to medical staff using real-time dosimetry coupled with visual radiation dose feedback during angiographic interventions. For this purpose, we analyzed a total of 214 angiographic examinations that consisted of chemoembolizations and several other types of therapeutic interventions. The Unfors RaySafe i2 dosimeter was worn by the interventionalist at chest height over the lead protection. A total of 110 interventions were performed with real-time radiation dosimetry allowing the interventionalist to react upon higher x-ray exposure and 104 examinations served as the comparative group without real-time radiation monitoring. By using the real-time display during interventions, the overall mean operator radiation dose decreased from 3.67 (IQR, 0.95–23.01) to 2.36 μSv (IQR, 0.52–12.66) (−36%; p = 0.032) at simultaneously reduced operator exposure time by 4.5 min (p = 0.071). Dividing interventions into chemoembolizations and other types of therapeutic interventions, radiation dose decreased from 1.31 (IQR, 0.46-3.62) to 0.95 μSv (IQR, 0.53-3.11) and from 24.39 (IQR, 12.14-63.0) to 10.37 μSv (IQR, 0.85-36.84), respectively, using live-screen dosimetry (p ≤ 0.005). Radiation dose reductions were also observed for the participating assistants, indicating that they could also benefit from real-time visual feedback dosimetry during interventions (−30%; p = 0.039). Integration of real-time dosimetry into clinical processes might be useful in reducing occupational radiation exposure time during angiographic interventions. The real-time visual feedback raised the awareness of interventionalists and their assistants to the potential danger of prolonged radiation exposure leading to the adoption of radiation-sparing practices. Therefore, it might create a safer environment for the medical staff by keeping the applied radiation exposure as low as possible.
Stimulation of renal collecting duct principal cells with antidiuretic hormone (arginine-vasopressin, AVP) results in inhibition of the small GTPase RhoA and the enrichment of the water channel aquaporin-2 (AQP2) in the plasma membrane. The membrane insertion facilitates water reabsorption from primary urine and fine-tuning of body water homeostasis. Rho guanine nucleotide exchange factors (GEFs) interact with RhoA, catalyze the exchange of GDP for GTP and thereby activate the GTPase. However, GEFs involved in the control of AQP2 in renal principal cells are unknown. The A-kinase anchoring protein, AKAP-Lbc, possesses GEF activity, specifically activates RhoA, and is expressed in primary renal inner medullary collecting duct principal (IMCD) cells. Through screening of 18,431 small molecules and synthesis of a focused library around one of the hits, we identified an inhibitor of the interaction of AKAP-Lbc and RhoA. This molecule, Scaff10-8, bound to RhoA, inhibited the AKAP-Lbc-mediated RhoA activation but did not interfere with RhoA activation through other GEFs or activities of other members of the Rho family of small GTPases, Rac1 and Cdc42. Scaff10-8 promoted the redistribution of AQP2 from intracellular vesicles to the periphery of IMCD cells. Thus, our data demonstrate an involvement of AKAP-Lbc-mediated RhoA activation in the control of AQP2 trafficking.
Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR–ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 106, 1.08±0.11 × 105, 1.03±0.10 × 104, 1.02±0.09 × 103, 1.04±0.10 × 102 and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR–ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR–ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).